Bioreactor Functions as Perfusion Mimic - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bioreactor Functions as Perfusion Mimic


Pharmaceutical Technology
Volume 37, Issue 12, pp. 14

TAP Biosystem’s ambr micro bioreactor system can be applied as a perfusion mimic to enable scientists to quickly develop large-scale perfusion culture processes of unstable, low producing or minimally expressing proteins or antibodies. This system can be used as a semi-continuous chemostat model for perfusion culture in 10-15 mL micro bioreactors by using the workstation’s integrated cell counter to monitor cell density and calculate both cell growth rates and dilution volumes required to maintain stable cell density. The liquid handling performs dilutions at appropriate time points, which automatically refines chemostasis throughout the culture process. The cell specific performance can then be extrapolated to full-scale perfusion cultures.

AP Biosystems

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here